4 Results for "

BET-IN-15

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "BET-IN-15" in MCE Product Catalog:

Cat. No.: HY-153945
CAS No.: 2408994-22-7
Research Areas:  

Cancer

BET-IN-15 (compound 1) is a potent and orally active BET inhibitor with IC50 values of 0.64,0.25 nM for BRD4-BD1,BRD4-BD2,respectively. BET-IN-15 shows antiproliferative activity .
loading...
    loading...
Cat. No.: HY-181729
Research Areas:  

Cancer

PROTAC BET Degrader-15 is a BET PROTAC degrader with DC50 values of <0.10 nM, <0.01 nM, and <0.01 nM against BRD2, BRD3, and BRD4, respectively. PROTAC BET Degrader-15 induces significant G2/M phase cell cycle arrest and triggers apoptosis. PROTAC BET Degrader-15 causes marked downregulation of c-Myc, accompanied by upregulation of the cell cycle inhibitory protein p21, downregulation of CDK6, and an increase in the apoptosis marker cleaved PARP. PROTAC BET Degrader-15 is applicable to the research of hematologic malignancies and lung cancer .
loading...
    loading...
Cat. No.: HY-181736
CAS No.: 2461559-77-1
Research Areas:  

Cancer

Pomalidomide-C2-piperazine-Boc is an E3 ligase ligand-linker conjugate that can be used to synthesize PROTACs, such as PROTAC BET Degrader-15 (HY-181729).
loading...
    loading...
Cat. No.: HY-181735
BET-IN-30 (Compound 11d) is a BTE family protein inhibitor, which can act as a BRD2/BRD3/BRD4 target protein ligand and be used for the synthesis of PROTACs, such as PROTAC BET Degrader-15 (HY-181729). BET-IN-30 exhibits potent anti-proliferative activity against acute myeloid leukemia (AML) cells such as MV4-11. BET-IN-30 can be used for the study of AML .
loading...
    loading...